profile

Oncology Hero

Microsoft Launches Cancer-Focused AI, Trodelvy Scores in Breast Cancer, CT Overuse Linked to Future Cancers

Published 3 months ago • 1 min read

​

​

Microsoft Unveils Agentic AI Platform for Personalized Cancer Care

Context: AI in oncology has largely focused on diagnostics and documentation—but orchestration of real-time, personalized care remains a major frontier.

What's New? Microsoft has launched an “agentic AI” orchestrator to assist oncologists with treatment decisions, patient navigation, and workflow optimization across cancer care. The technology integrates Copilot, Nuance, and Azure platforms with cancer center data streams.

Why it Matters? This move positions Microsoft at the intersection of oncology and enterprise AI, aiming to improve coordination, reduce burnout, and support precision care in real-world cancer settings.

​Read More​

Trodelvy Hits Efficacy Benchmark in Breast Cancer Monotherapy Trial

Context: Following a successful combo with Keytruda, Gilead’s Trodelvy continues to expand its footprint in breast cancer as a standalone agent.

What's New? In the TROPION-Breast01 trial, Trodelvy met its primary endpoint as monotherapy in pretreated HR+/HER2- breast cancer, extending progression-free survival and reinforcing its role beyond triple-negative disease.

Why it Matters? The results could support label expansion and position Trodelvy as a foundational ADC therapy across broader breast cancer subtypes, increasing its commercial and clinical impact.

​Read More​

CT Scan Overuse May Account for 5% of Future Cancer Cases

Context: The use of CT imaging has grown dramatically over the past two decades, raising concerns about cumulative radiation exposure.

What's New? A modeling study estimates that up to 5% of future cancers could be attributed to overuse of CT scans, particularly among younger patients who face longer-term radiation risk.

Why it Matters? These findings may prompt reassessment of imaging guidelines and encourage more judicious use of CT in routine and follow-up care, balancing diagnostic yield against long-term risk.

​Read More​

Merck Secures Third FDA Approval for Welireg in Renal Cell Carcinoma

Context: Welireg (belzutifan) is a HIF-2α inhibitor developed for renal cancers and inherited tumor syndromes.

What's New? Merck has received its third FDA approval for Welireg, now indicated for previously treated advanced renal cell carcinoma (RCC). The approval follows strong efficacy results in this population and builds on Merck’s 2019 acquisition of Peloton Therapeutics.

Why it Matters? The expanded indication solidifies Welireg’s role in the RCC landscape and adds to Merck’s strategic positioning in rare and aggressive tumor types.

​Read More​

​

Oncology Hero

Sharing the latest updates in oncology

Read more from Oncology Hero

Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...

5 days ago • 2 min read

Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...

3 months ago • 1 min read

Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options. What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024. Why it Matters? These findings position...

3 months ago • 1 min read